ClinicalTrials.gg
CompletedNCT01831817Updated Mar 26, 2015Results posted

Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

A Phase 2 interventional study of 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice and 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice in Dentinal Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-26.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.

Read the detailed description

This will be a single center, eight week, randomized, controlled, examiner blind, four treatment arms, parallel design study in participants with at least two sensitive teeth that meet all the criteria at the Screening and Baseline visit. Participants will be assessed at baseline, four and eight weeks to monitor clinical efficacy and safety.

02

Conditions studied

  • Dentinal Hypersensitivity
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study.
  • Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Specific Dentition Exclusions for Test teeth

    1. Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of Screening.
    2. Tooth with exposed dentin but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing etiologies other than erosion, abrasion or recession of exposed dentin.
    3. Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice in the opinion of the investigator
  • Use of a sensitivity dentifrice within 8 weeks of screening
  • Individuals who require antibiotic prophylaxis for dental procedures
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    5% calcium sodium phosphosilicate/ sodium monofluorophosphate

    Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

    Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

  • Active comparator
    0% calcium sodium phosphosilicate/sodium monofluorophosphate

    Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

    Drug: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

  • Active comparator
    Sodium monofluorophosphate

    Dentifrice containing 1000 ppmF as sodium monofluorophosphate

    Drug: Sodium monofluorophosphate dentifrice

  • Active comparator
    Sodium fluoride

    Dentifrice containing 1100 ppmF as sodium fluoride

    Drug: Sodium Fluoride dentifrice

Interventions

  • Drug5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

    Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate

  • Drug0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

    No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate

  • Sodium monofluorophospate dentifrice (1000 ppm F)

  • Dentifrice containing 1100ppm F as sodium fluoride

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Schiff Sensitivity Score at Week 4

    Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline and 4 weeks post administration of study treatment

  2. Mean Change From Baseline in Schiff Sensitivity Score at Week 8

    Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline and 8 weeks post administration of study treatment

  3. Median Change From Baseline in Tactile Sensitivity at Week 4

    Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

    Time frame: Baseline and 4 weeks post administration of study treatment

  4. Median Change From Baseline in Tactile Sensitivity at Week 8

    Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

    Time frame: Baseline and 8 weeks post administration of study treatment

  5. Mean Change From Baseline in Visual Rating Scale Score at Week 4

    The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

    Time frame: Baseline and 4 weeks post administration of study treatment

  6. Mean Change From Baseline in Visual Rating Scale Score at Week 8

    The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

    Time frame: Baseline and 8 weeks post administration of study treatment

Secondary outcomes

  1. Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire Total Score at Week 4

    DHEQ Total score is an overall summary measure for the impact of dentine hypersensitivity on everyday life. Total score is calculated as the sum of 34 questions (each with a possible score of 1 to 7). The scale of responses range from 34 to 238. Higher values imply a worse outcome i.e. an increase in impact on dentine hypersensitivity on everyday life. Lower values imply a better outcome i.e. a decrease in impact on dentine hypersensitivity on everyday life.

    Time frame: Baseline and 4 weeks post administration of study treatment

  2. Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score at Week 8

    DHEQ Total score is an overall summary measure for the impact of dentine hypersensitivity on everyday life. Total score is calculated as the sum of 34 questions (each with a possible score of 1 to 7). The scale of responses range from 34 to 238. Higher values imply a worse outcome i.e. an increase in impact on dentine hypersensitivity on everyday life. Lower values imply a better outcome i.e. a decrease in impact on dentine hypersensitivity on everyday life.

    Time frame: Baseline and 8 weeks post administration of study treatment

07

Results

Posted Mar 26, 2015

Participant flow

Participants were recruited at the clinical site

Participant flow — Overall Study
Milestone5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Started35343536
Completed31343536
Not completed4000
Withdrew: Lost to follow-up1000
Withdrew: Withdrawl of consent3000

Outcome measures

PrimaryMean Change From Baseline in Schiff Sensitivity Score at Week 4

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline and 4 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Schiff Sensitivity Score at Week 4
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline2.39 ± 0.3962.41 ± 0.4352.40 ± 0.4172.38 ± 0.403
Week 41.83 ± 0.7791.94 ± 0.5472.31 ± 0.5162.31 ± 0.401
Mean change from baseline at Week 4-0.56 ± 0.759-0.47 ± 0.563-0.09 ± 0.445-0.07 ± 0.341
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · ANCOVA · p = 0.4321 · Mean change difference: -0.10 · 95% CI -0.35 to 0.15Treatment as fixed factor and baseline Schiff score as covariate. Difference was First named treatment-second named treatment that a negative difference implied the mean of the second named treatment was larger than that of the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.0002 · Mean change difference: -0.48 · 95% CI -0.73 to -0.23Treatment as fixed factor and baseline Schiff score as covariate. Difference is First named treatment - second named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0002 · Mean change difference: -0.49 · 95% CI -0.74 to -0.24Treatment as fixed factor and baseline Schiff score as covariate. Difference is First named treatment - second named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.0028 · Mean change difference: 0.38 · 95% CI 0.13 to 0.63Treatment as fixed factor and baseline Schiff score as covariate. Difference is second named treatment - first named treatment that a negative difference implies the mean of the first named treatment is larger than that of the second named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0022 · Mean change difference: 0.39 · 95% CI 0.14 to 0.63Treatment as fixed factor and baseline Schiff score as covariate. Difference is Second named treatment - first named treatment that a negative difference implies the mean of the first named treatment is larger than that of the second named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.9606 · Mean change difference: -0.01 · 95% CI -0.25 to 0.24Treatment as fixed factor and baseline Schiff score as covariate. Difference is Second named treatment - first named treatment that a negative difference implies the mean of the first named treatment is larger than that of the second named treatment
PrimaryMean Change From Baseline in Schiff Sensitivity Score at Week 8

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline and 8 weeks post administration of study treatment
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in Schiff Sensitivity Score at Week 8
Score on a Scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline2.40 ± 0.3962.41 ± 0.4352.40 ± 0.4172.38 ± 0.403
Week 81.60 ± 0.9871.56 ± 0.8942.41 ± 0.4622.44 ± 0.427
Mean change from baseline at Week 8-0.81 ± 0.972-0.85 ± 0.9010.01 ± 0.3530.07 ± 0.450
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · ANCOVA · p = 0.8030 · Mean change difference: 0.04 · 95% CI -0.30 to 0.38Treatment as fixed factor and baseline Schiff score as covariate. Difference is First named treatment - second named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = <0.0001 · Mean change difference: -0.82 · 95% CI -1.16 to -0.48Treatment as fixed factor and baseline Schiff score as covariate. Difference is First named treatment - second named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = <0.0001 · Mean change difference: -0.86 · 95% CI -1.20 to -0.53Treatment as fixed factor and baseline Schiff score as covariate. Difference is First named treatment - second named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = <0.0001 · Mean change difference: 0.86 · 95% CI 0.53 to 1.19Treatment as fixed factor and baseline Schiff score as covariate. Difference is Second named treatment - first named treatment that a negative difference implies the mean of the first named treatment is larger than that of the second named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = <0.0001 · Mean change difference: 0.91 · 95% CI 0.58 to 1.23Treatment as fixed factor and baseline Schiff score as covariate. Difference is Second named treatment - first named treatment that a negative difference implies the mean of the second named treatment is larger than that of the first named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.7872 · Mean change difference: -0.04 · 95% CI -0.37 to 0.28Treatment as fixed factor and baseline Schiff score as covariate. Difference is Second named treatment - first named treatment that a negative difference implies the mean of the first named treatment is larger than that of the second named treatment
PrimaryMedian Change From Baseline in Tactile Sensitivity at Week 4

Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

Time frame:
Baseline and 4 weeks post administration of study treatment
Reported as:
Median · grams
Median Change From Baseline in Tactile Sensitivity at Week 4
grams5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline10.00 (10.0 to 10.0)10.00 (10.0 to 10.0)10.00 (10.0 to 15.0)10.00 (10.0 to 15.0)
Week 410.00 (10.0 to 45.0)10.00 (10.0 to 50.0)10.00 (10.0 to 15.0)10.00 (10.0 to 35.0)
Median change from baseline at Week 40.00 (0.0 to 35.0)0.00 (0.0 to 40.0)0.00 (-5.0 to 5.0)0.00 (-5.0 to 20.0)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = 0.9642 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 0.00Positive values favour the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0016 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 5.00Positive values favour the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0100 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 5.00Positive values favour the first named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0020 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 0.00Positive values favour the second named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0122 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 0.00Positive values favour the second named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.7138 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 0.00Positive values favour the first named treatment
PrimaryMedian Change From Baseline in Tactile Sensitivity at Week 8

Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

Time frame:
Baseline and 8 weeks post administration of study treatment
Reported as:
Median · grams
Median Change From Baseline in Tactile Sensitivity at Week 8
grams5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline10.00 (10.0 to 10.0)10.00 (10.0 to 10.0)10.00 (10.0 to 15.0)10.00 (10.0 to 15.0)
Week 815.00 (10.0 to 90.0)15.00 (10.0 to 75.0)10.00 (10.0 to 55.0)10.00 (10.0 to 35.0)
Median change from baseline at Week 85.00 (0.0 to 80.0)5.00 (0.0 to 65.0)0.00 (-5.0 to 45.0)0.00 (0.0 to 20.0)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = 0.9834 · Hodges-lehmann shift: 0.00 · 95% CI -5.00 to 5.00Positive values favour the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0001 · Hodges-lehmann shift: 5.00 · 95% CI 0.00 to 15.00Positive values favour the first named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0003 · Hodges-lehmann shift: 2.50 · 95% CI 0.00 to 15.00Positive values favour the first named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Hodges-Lehmann Wilcoxon non-parametric · p = <0.0001 · Hodges-lehmann shift: -5.00 · 95% CI -10.00 to 0.00Positive values favour the second named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.0002 · Hodges-lehmann shift: -5.00 · 95% CI -10.00 to 0.00Positive values favour the second named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · Hodges-Lehmann Wilcoxon non-parametric · p = 0.2894 · Hodges-lehmann shift: 0.00 · 95% CI 0.00 to 0.00Positive values favour the first named treatment
PrimaryMean Change From Baseline in Visual Rating Scale Score at Week 4

The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

Time frame:
Baseline and 4 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Visual Rating Scale Score at Week 4
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline6.66 ± 1.8866.69 ± 1.7236.41 ± 1.7766.92 ± 1.783
Week 45.45 ± 2.2125.72 ± 1.7765.39 ± 1.7026.38 ± 1.814
Mean change from baseline at Week 4-1.20 ± 1.727-0.97 ± 2.371-1.03 ± 1.356-0.54 ± 1.742
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · ANCOVA · p = 0.5555 · Mean change difference: -0.24 · 95% CI -1.03 to 0.56Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.8769 · Mean change difference: -0.06 · 95% CI -0.86 to 0.73Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0562 · Mean change difference: -0.76 · 95% CI -1.55 to 0.02Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.6562 · Mean change difference: -0.18 · 95% CI -0.95 to 0.60Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.1788 · Mean change difference: 0.53 · 95% CI -0.24 to 1.30Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0734 · Mean change difference: -0.70 · 95% CI -1.47 to 0.07Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
PrimaryMean Change From Baseline in Visual Rating Scale Score at Week 8

The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

Time frame:
Baseline and 8 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Visual Rating Scale Score at Week 8
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline6.71 ± 1.8926.69 ± 1.7236.41 ± 1.7766.92 ± 1.783
Week 84.65 ± 2.5504.46 ± 2.0765.70 ± 1.9146.07 ± 2.046
Mean change from baseline at Week 8-2.06 ± 2.205-2.24 ± 2.287-0.71 ± 1.559-0.86 ± 1.673
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate · ANCOVA · p = 0.6727 · Mean change difference: 0.19 · 95% CI -0.71 to 1.10Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.0072 · Mean change difference: -1.24 · 95% CI -2.14 to -0.34Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0056 · Mean change difference: -1.27 · 95% CI -2.16 to -0.38Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.0016 · Mean change diference: 1.43 · 95% CI 0.56 to 2.31Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • 0% Calcium Sodium Phosphosilicate/Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.0011 · Mean change difference: 1.46 · 95% CI 0.59 to 2.33Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.9413 · Mean change difference: -0.03 · 95% CI -0.90 to 0.84Treatment as fixed factor. Baseline Schiff strata and VRS as covariates. Difference is 1st named treatment - 2nd named treatment that a negative difference implies the mean of the 2nd named treatment is larger than that of the 1st named treatment
SecondaryMean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire Total Score at Week 4

DHEQ Total score is an overall summary measure for the impact of dentine hypersensitivity on everyday life. Total score is calculated as the sum of 34 questions (each with a possible score of 1 to 7). The scale of responses range from 34 to 238. Higher values imply a worse outcome i.e. an increase in impact on dentine hypersensitivity on everyday life. Lower values imply a better outcome i.e. a decrease in impact on dentine hypersensitivity on everyday life.

Time frame:
Baseline and 4 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire Total Score at Week 4
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline136.53 ± 34.194132.55 ± 35.646121.09 ± 44.467133.89 ± 33.638
Mean change from baseline at Week 4-3.91 ± 21.850-4.39 ± 27.155-3.80 ± 24.874-7.50 ± 28.905
SecondaryMean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score at Week 8

DHEQ Total score is an overall summary measure for the impact of dentine hypersensitivity on everyday life. Total score is calculated as the sum of 34 questions (each with a possible score of 1 to 7). The scale of responses range from 34 to 238. Higher values imply a worse outcome i.e. an increase in impact on dentine hypersensitivity on everyday life. Lower values imply a better outcome i.e. a decrease in impact on dentine hypersensitivity on everyday life.

Time frame:
Baseline and 8 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score at Week 8
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Baseline134.33 ± 33.778132.55 ± 35.646120.09 ± 44.614133.89 ± 33.638
Change from baseline at Week 8-6.43 ± 28.693-7.97 ± 31.324-3.88 ± 22.222-10.86 ± 33.669

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate—0/35 (0%)5/35 (14.3%)
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate—0/34 (0%)3/34 (8.8%)
Sodium Monofluorophosphate—0/35 (0%)2/35 (5.7%)
Sodium Fluoride—0/36 (0%)2/36 (5.6%)
Most frequent other events
Showing 10 of 17
Most frequent other events
Event5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
HeadacheNervous system disorders1/352/341/352/36
NasopharyngitisRespiratory, thoracic and mediastinal disorders2/350/340/350/36
SinusitisInfections and infestations0/351/340/350/36
ArthralgiaImmune system disorders1/350/340/350/36
ConstipationGastrointestinal disorders1/350/340/350/36
Oral HerpesInfections and infestations1/350/340/350/36
Urinary Tract InfectionsInfections and infestations1/350/340/350/36
Bone PainMusculoskeletal and connective tissue disorders1/350/340/350/36
Muscle SpasmsMusculoskeletal and connective tissue disorders1/350/340/350/36
PainGeneral disorders1/350/340/350/36

Baseline characteristics

ITT population consisted of all subjects who were randomized, administered at least one study treatment and provided at least one post-baseline assessment of efficacy. The data of 1 subject in 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate group who was lost to follow up was included in the ITT population.

Age, Continuous
Age, Continuous(Years)5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium FluorideTotal
Mean36.9 ± 10.0839.6 ± 9.7238.3 ± 8.7342.7 ± 9.1039.5 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/Sodium MonofluorophosphateSodium MonofluorophosphateSodium FluorideTotal
Female28322830118
Male427619
08

Study locations

1 site
  • Salus Research, Inc.
    Fort Wayne, Indiana 46825, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2013
First posted
Apr 15, 2013
Start
Jan 2013
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Mar 26, 2015
Last update
Mar 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01831817
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 15, 2013
Start date
Jan 2013
Primary completion
May 2013
Completion
May 2013
Results posted
Mar 26, 2015
Last update
Mar 26, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion